Atelerix Life Sciences
Indianapolis, US · Founded 2020 · Delaware corporation · 1 known investors
Atelerix Life Sciences develops novel respiratory therapies for drug-induced respiratory depression, respiratory disease exacerbations, and bio-defense against respiratory threats. The company is advancing pre-clinical and clinical-stage drug candidates, with ATLX-0199 as its lead compound designed to stimulate respiratory drive while preserving pain relief and sedation.
Founders & leadership
DK
David KalergisExecutive Officer, Director, Promoter
WA
William AkridgeDirector
PB
Peter Barton HuttDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$650KraisedOct 2022 · 2 investors · BiotechnologyRule 506(b)
▶$650KraisedOct 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David KalergisExecutive Officer, Director, Promoter
- William AkridgeDirector
- Peter Barton HuttDirector
- Offering amount
- $3.5M
- Amount sold
- $650K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.